Kristin D Marciante

Summary

Publications

  1. pmc Cerivastatin, genetic variants, and the risk of rhabdomyolysis
    Kristin D Marciante
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98101, USA
    Pharmacogenet Genomics 21:280-8. 2011
  2. doi request reprint Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke
    Kristin D Marciante
    Cardiovascular Health Research Unit, Seattle, Washington 98101, USA
    Pharmacogenet Genomics 18:535-43. 2008
  3. pmc Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke
    Lucia A Hindorff
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA
    Pharmacogenet Genomics 18:677-82. 2008
  4. ncbi request reprint Renin-angiotensin system haplotypes and the risk of myocardial infarction and stroke in pharmacologically treated hypertensive patients
    Kristin D Marciante
    Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA
    Am J Epidemiol 166:19-27. 2007
  5. pmc Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke
    Joshua C Bis
    Department of Medicine, University of Washington, Seattle, WA 981041, USA
    Atherosclerosis 198:166-73. 2008
  6. doi request reprint beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke
    Rozenn N Lemaitre
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA
    Am J Hypertens 21:290-6. 2008
  7. ncbi request reprint Association of genetic variations with nonfatal venous thrombosis in postmenopausal women
    Nicholas L Smith
    Department of Epidemiology, University of Washington, Seattle, WA 98101, USA
    JAMA 297:489-98. 2007
  8. pmc Human liver expression of CYP2C8: gender, age, and genotype effects
    Suresh Babu Naraharisetti
    Departments of Medicinal Chemistry, University of Washington, Seattle, WA 98195 7610, USA
    Drug Metab Dispos 38:889-93. 2010
  9. doi request reprint OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis
    Bani Tamraz
    Cardiovascular Research Institute, University of California, San Francisco, California, USA
    Pharmacogenet Genomics 23:355-64. 2013
  10. pmc Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5
    Rüdiger Kaspera
    Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195 7610, USA
    Biochem Pharmacol 82:681-91. 2011

Detail Information

Publications12

  1. pmc Cerivastatin, genetic variants, and the risk of rhabdomyolysis
    Kristin D Marciante
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98101, USA
    Pharmacogenet Genomics 21:280-8. 2011
    ..The bimodal response, rhabdomyolysis in a small proportion of users, points to genetic factors as a potential cause. We conducted a case-control study to evaluate genetic markers for cerivastatin-associated rhabdomyolysis...
  2. doi request reprint Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke
    Kristin D Marciante
    Cardiovascular Health Research Unit, Seattle, Washington 98101, USA
    Pharmacogenet Genomics 18:535-43. 2008
    ..We conducted a population-based, case-control study at Group Health to determine whether common genetic variation in the CYP2J2, CYP2C8, and CYP2C9 genes was associated with the risk of myocardial infarction and ischemic stroke...
  3. pmc Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke
    Lucia A Hindorff
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA
    Pharmacogenet Genomics 18:677-82. 2008
    ....
  4. ncbi request reprint Renin-angiotensin system haplotypes and the risk of myocardial infarction and stroke in pharmacologically treated hypertensive patients
    Kristin D Marciante
    Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA
    Am J Epidemiol 166:19-27. 2007
    ..17). In this case-control study, RAS gene haplotypes were not significantly associated with increased risks of myocardial infarction or stroke...
  5. pmc Variation in inflammation-related genes and risk of incident nonfatal myocardial infarction or ischemic stroke
    Joshua C Bis
    Department of Medicine, University of Washington, Seattle, WA 981041, USA
    Atherosclerosis 198:166-73. 2008
    ....
  6. doi request reprint beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke
    Rozenn N Lemaitre
    Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, Washington, USA
    Am J Hypertens 21:290-6. 2008
    ..The benefits of beta-blocker therapy may depend on underlying genetic susceptibility...
  7. ncbi request reprint Association of genetic variations with nonfatal venous thrombosis in postmenopausal women
    Nicholas L Smith
    Department of Epidemiology, University of Washington, Seattle, WA 98101, USA
    JAMA 297:489-98. 2007
    ....
  8. pmc Human liver expression of CYP2C8: gender, age, and genotype effects
    Suresh Babu Naraharisetti
    Departments of Medicinal Chemistry, University of Washington, Seattle, WA 98195 7610, USA
    Drug Metab Dispos 38:889-93. 2010
    ..CYP2C8 mRNA or protein expression levels were not significantly affected by CYP2C8*3 or *4 genotype, gender, or age, and variation observed clinically in CYP2C8 activity warrants further investigation...
  9. doi request reprint OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis
    Bani Tamraz
    Cardiovascular Research Institute, University of California, San Francisco, California, USA
    Pharmacogenet Genomics 23:355-64. 2013
    ....
  10. pmc Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5
    Rüdiger Kaspera
    Department of Medicinal Chemistry, University of Washington, Seattle, WA 98195 7610, USA
    Biochem Pharmacol 82:681-91. 2011
    ..In silico studies illustrate the genetic differences between wild type and variant on the molecular level...
  11. pmc Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction
    Nona Sotoodehnia
    Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA
    Nat Genet 42:1068-76. 2010
    ..These findings extend our current knowledge of ventricular depolarization and conduction...
  12. ncbi request reprint Logic regression for analysis of the association between genetic variation in the renin-angiotensin system and myocardial infarction or stroke
    Charles Kooperberg
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Am J Epidemiol 165:334-43. 2007
    ....